Active Not RecruitingNCT06869187
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolarity in Adults
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Walnut Creek and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 28, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 35
- Sponsor
- Autobahn Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06869187
- Official title
Show the full official title
A Phase 2 Open-label Study of the Effect of Adjunctively Administered ABX-002 in Adults With Bipolar Disorder Experiencing an Episode of Depression
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Walnut Creek · Cromwell · Hartford
10 more locations
- Miami
- Chicago
- Worcester
- Cherry Hill
- Hamilton
- Marlton
- Brooklyn
- New York
- Staten Island
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Autobahn Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including ABX-002.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
